WNK2 and melanoma: Thus, BRAF inhibitors (BRAFi), such as vemurafenib or dabrafenib, together with inhibitors of the mitogen-activated protein kinase (MEK) (i.e., trametinib), a BRAF downstream effector, have been successfully employed in patients with advanced mutated BRAF melanoma diseases [6].